Table 3.

Sensitivity analysis: rate of incident cancers in patients with prior malignancy: followup censored after first incident malignancy^*

	DMARD (n = 117)	All anti-TNF (n = 177)
Person-years of followup	232	503
Person-years followup per patient, median (IQR)	1.8 (1.3–2.6)	3.0 (1.9–3.9)
Incident malignancies, no.	9	11
Patients with incident malignancies, no.	9	11
Rate of incident malignancy/1,000 person-years (95% CI)	38.7 (17.7–73.5)	21.9 (10.9–39.2)
IRR (95% CI)	Referent	0.51 (0.2–1.27)
IRR adjusted for age and sex (95% CI)	Referent	0.52 (0.21–1.33)
Propensity-adjusted IRR (95% CI)	Referent	0.47 (0.10–2.22)

^*DMARD = disease-modifying antirheumatic drug; anti-TNF = anti–tumor necrosis factor; IQR = interquartile range; 95% CI = 95% confidence interval; IRR = incidence rate ratio.